U.S. markets close in 3 hours 17 minutes
  • S&P 500

    3,850.72
    +21.38 (+0.56%)
     
  • Dow 30

    31,240.30
    -161.71 (-0.51%)
     
  • Nasdaq

    13,315.53
    +196.10 (+1.49%)
     
  • Russell 2000

    2,221.32
    +21.15 (+0.96%)
     
  • Crude Oil

    62.33
    -1.20 (-1.89%)
     
  • Gold

    1,720.50
    -54.90 (-3.09%)
     
  • Silver

    26.30
    -1.39 (-5.00%)
     
  • EUR/USD

    1.2080
    -0.0106 (-0.87%)
     
  • 10-Yr Bond

    1.4940
    -0.0240 (-1.58%)
     
  • GBP/USD

    1.3950
    -0.0063 (-0.45%)
     
  • USD/JPY

    106.6780
    +0.4480 (+0.42%)
     
  • BTC-USD

    47,848.23
    -3,225.78 (-6.32%)
     
  • CMC Crypto 200

    959.37
    +26.23 (+2.81%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

HAMILTON, Bermuda, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (KNSA) announced today that Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa, will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time at the Westin St. Francis Hotel in San Francisco, California. The presentation will be followed by a question and answer session that will begin at 2:30 p.m. Pacific Time / 5:30 p.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa has a pipeline of product candidates across various stages of development, focused on autoinflammatory and autoimmune conditions. For more information, please visit www.kiniksa.com.

Every Second Counts!™

Kiniksa Investor and Media Contact
Mark Ragosa
(781) 430-8289
mragosa@kiniksa.com